The impact of co‐morbidity burden on appropriate implantable cardioverter defibrillator therapy and all‐cause mortality: insight from Danish nationwide clinical registers

Abstract

Increasing co-morbidity burden was not associated with increased risk of appropriate ICD therapy. With increasing co-morbidity burden, mortality increased, and a higher proportion of patients died, without ever having utilized their device.

Determinants of outcomes following outpatient placement of implantable cardioverter defibrillators in a Medicare Advantage population

“…This seems consistent with a reported weighted mortality of 15% over a mean of approximately 4 years in a meta‐analysis of trials of ICD for primary prevention (weighted mean age, 61 years) . Likewise, another study reported 4‐year mortality rates from 7% to 52%, depending on whether recipients of either primary or secondary ICD (mean age 62 years) had no comorbidities for indications unrelated to ICDs or had more than two such comorbidities . The present study's findings regarding patient‐related factors are generally consistent with the literature.…”

“…11 Likewise, another study reported 4-year mortality rates from 7% to 52%, depending on whether recipients of either primary or secondary ICD (mean age 62 years) had no comorbidities for indications unrelated to ICDs or had more than two such comorbidities. 12 The present study's findings In the present study, despite having fewer device-related complications, men were 24% less likely to survive the first year. In contrast, a regional database analysis did not find evidence supporting an association between sex and mortality.…”

Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter‐defibrillator therapies and hospitalizations

“…. .worst prognosis in patients with ICD,32 our results reinforce the proposal25,31 of AVJA in patients with HF, permanent AF and candidates for CRT who are not responding to rate control agents.…”

Highlights in heart failure

“…101,102,188,189 The contribution of comorbidities to patients' outcomes may be similar in patients with HFrEF, compared with those with HFpEF, 189 or be larger in those with HFpEF according to other analyses. 101,102,188,189 The contribution of comorbidities to patients' outcomes may be similar in patients with HFrEF, compared with those with HFpEF, 189 or be larger in those with HFpEF according to other analyses.…”